drugset / Trial / NCT03104621

Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients

NCT03104621

Phase 4 Completed 20 enrolled Gangnam Severance Hospital
RandomizedCrossoverQuadruple-blindTreatment

Summary

The aim of this work is to evaluate efficacy and tolerability of preservative containing 0.0015% tafluprost and preservative-free 0.0015% tafluprost. Both preservative containing and preservative-free 0.0015% tafluprost will reduce intraocular pressure significantly. In addition, preservative-free 0.0015% tafluprost might improve tolerability of glaucoma patients.

Timeline

Start
2013-03
Primary completion
2014-09
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject BENZALKONIUM Small molecule 0.001 %
Subject Tafluprost Other / unclassified 0.0015 % Topical

Indications